- Home
- EDSA vs CLRB Comparison
EDSA vs CLRB Comparison
Compare EDSA & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDSA | CLRB |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 12.9M |
| IPO Year | 2018 | 2008 |
Fundamental Metrics
Financial Performance| Metric | EDSA | CLRB |
|---|---|---|
| Price | $6.26 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | ★ 7.0M | 37.0K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.23 |
| 52 Week High | $8.74 | $10.19 |
Technical Indicators
Market Signals| Indicator | EDSA | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 75.75 | 52.55 |
| Support Level | $1.71 | $3.19 |
| Resistance Level | N/A | $3.60 |
| Average True Range (ATR) | 1.12 | 0.29 |
| MACD | 0.48 | 0.00 |
| Stochastic Oscillator | 69.30 | 57.64 |
Price Performance
Historical ComparisonAbout EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.